Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Vir Biotechnology (VIR – Research Report), MacroGenics (MGNX – Research Report) and Outlook Therapeutics (OTLK – Research Report).
Vir Biotechnology (VIR)
In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Vir Biotechnology, with a price target of $95.00. The company’s shares closed last Monday at $8.63, close to its 52-week low of $7.72.
According to TipRanks.com, Trucchio is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Vir Biotechnology with a $32.86 average price target, representing a 274.7% upside. In a report issued on November 2, Leerink Partners also maintained a Buy rating on the stock with a $24.00 price target.
See the top stocks recommended by analysts >>
MacroGenics (MGNX)
BTIG analyst Kaveri Pohlman maintained a Buy rating on MacroGenics yesterday and set a price target of $12.00. The company’s shares closed last Monday at $5.44.
According to TipRanks.com, Pohlman has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on MacroGenics is a Strong Buy with an average price target of $12.80, representing a 137.0% upside. In a report released today, JMP Securities also maintained a Buy rating on the stock with a $10.00 price target.
Outlook Therapeutics (OTLK)
BTIG analyst Julian Harrison maintained a Hold rating on Outlook Therapeutics yesterday. The company’s shares closed last Monday at $0.45, close to its 52-week low of $0.20.
According to TipRanks.com, Harrison is a 1-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Outlook Therapeutics with a $1.38 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on VIR:
- Vir Biotechnology price target lowered to $27 from $41 at Barclays
- Vir Biotechnology files automatic mixed securities shelf
- Vir Biotechnology reports Q3 EPS ($1.22), consensus ($1.21)
- Vir Biotechnology appoints Jennifer Towne, Ph.D., as Chief Scientific Officer
- Vir Biotechnology to Participate in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference
